Modified release coated capsules

ABSTRACT

The present invention relates to a modified release coated capsule and a process to obtain that capsule.

PRIORITY

This application corresponds to the U.S. national phase of InternationalApplication No. PCT/EP2015/060638, filed May 13, 2015, which, in turn,claims priority to European Patent Application No. 14.168871.3 filed May19, 2014, the contents of which are incorporated by reference herein intheir entirety.

FIELD OF THE INVENTION

The present invention relates to a modified release coated capsule and aprocess to obtain that capsule.

BACKGROUND OF THE INVENTION

When orally administered, pharmaceutical preparations are generallydisintegrated in the stomach. However, when a certain release profile ofthe pharmaceutical or nutritional ingredient is desired, oralpharmaceutical preparations can be coated with a so-called functional ormodified release coating to achieve delayed or controlled release of anactive pharmaceutical ingredient (API). Those coatings intended toprotect the drug from the acidic environment of the gastric medium, toprevent the drug release in the stomach, or to provide release of anactive ingredient to certain and specific section of thegastrointestinal tract (GIT) as e.g. the jejunum, duodenum, ileum, thecolon and the rectum are commonly called delayed release coatingformulations using enteric polymers.

In contrast to delayed drug release coatings, controlled releasecoatings are requested to control the release of the drug over aprolonged period of time. Depending on the drug release mechanism,controlled release approaches are also known in the pharmaceutical areaas sustained, extended and prolonged release, respectively. Combinationsof these coatings are possible as well.

Attempts have been made to provide drug-filled hard capsules with amodified release coating. During this development precoatings were foundto be necessary because of imperfect adhesion of modified releasecoatings on hard gelatin capsules (K. S. Murthy et al., Pharm. Tech. 10,36 (1986)). However, a precoating has the disadvantage of requiring morepreparation steps resulting in more preparation time and material to beused, higher energy consumption and higher costs.

To overcome the disadvantages associated with a precoating, U.S. Pat.No. 4,670,287 discloses a method of film coating hard capsules under avacuum. However, because of high technical efforts this technique hasits limitations in industrial applicability.

In an alternative approach to overcome the disadvantages of precoatingsenteric coated HPMC (hydroxypropyl methylcellulose) capsules weresuggested to achieve intestinal targeting (E. T. Cole et al., Int. J.Pharm. 231 (2002) 83-95). Prior to the coating, the capsules were sealedwith the LEMs (liquid encapsulation by microspray) process. Entericcoatings with an amount of enteric polymer of at least 6 mg/cm² showedno pores or cracks. However, E. T. Cole et al reported that due to thegood compatibility between HPMC and the enteric films, variation incoating levels showed little influence on the dissolution profiles.

Furthermore, liquid filled capsules are frequently sealed either byusing a band or using the LEMs technology to avoid leakage duringfurther manufacturing steps, such as coating steps, packaging and so on.For powder or granules filled capsules, normally a band or other seal isnot considered, even if a coating process is involved, as there is lessrisk of capsule opening.

WO 2013/054285 discloses gastroretentive dosage systems wherein theextended-release layer comprises one or more extended-release polymer(s)and one or more coating additive(s). The system can be a band sealedcapsule which is coated with an extended-release coating being applieduntil there is a weight gain of up to 15% w/w based on the total weightof the dosage form.

WO 2004/030652 discloses compositions having an inner core and at leasttwo surrounding layers. The inner core may be a capsule which may besealed via banding or LEMS. The inner layer may be a continuous coatinghaving a coating weight of up to 25 mg/cm². The outer layer may be a waxat a coating weight of about 10 mg/cm².

WO 03/017940 discloses oral pharmaceutical formulations that deliver afirst puls of drug combined with a penetration enhancer and a secondpulse of penetration enhancer to promote absorbtion of drug, which isnot absorbed upon release with the first pulse of penetration enhancer.

Thus, there is still a need for further improved release coatedcapsules. In particular, it would be desirable to provide modifiedrelease coated capsules which can be easily prepared at reduced costsusing usual manufacturing processes. Furthermore, it would be desirableto provide a modified release coated capsule which can be prepared bythe same method and with the same coating materials independent of thecapsule shell material. Additionally, it would be desirable to provide amodified release coated capsule with a drug release profile which can beeasily tailored according to the requirements.

SUMMARY OF THE INVENTION

It has now surprisingly been found that the above and other problems canbe solved by applying a modified release coating onto the capsule shellof a capsule comprising a band seal and containing a non-liquid fill.

The present invention therefore relates to a capsule containing anon-liquid fill and comprising a modified release coating, characterizedin that the capsule is band sealed below the modified release coating.

While applicants do not wish to be bound to any theory it is believedthat the imperfect adhesion of enteric coatings on capsule shells mightat least partly be associated to the gap between the body and the cap ofthe capsule. At this gap, mechanical stress might occur leading topossible cracks in the coating and reduced adhesion of the coating.Sealing the gap with a band surprisingly allowed to directly apply theenteric coating onto the capsule shell without any precoat between thecapsule shell and the enteric coating. Furthermore, it was found thatsealing the gap by a band allows the reduction of the amount of entericpolymer required for obtaining the same or even improved level ofenteric coating compared to prior art coatings. This has the advantagethat manufacturing costs are not only reduced by omitting the precoat,but can additionally be reduced by reducing the amount of entericpolymer. This reduction has the further advantage that the thickness ofthe enteric coating can be reduced thereby reducing the overall size andweight of the final capsule. Additionally, based on this inventionresistance to release under simulated stomach conditions can be achievedalready with very thin enteric coating films. In this context, theinvention is of further advantage for tailoring drug release profile byadjusting the coating thickness according to the desired area of releasewithin the gastrointestinal tract.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows capsules according to example 1 and according tocomparative example 1A after immersion into acid solution.

FIG. 2 shows capsules according to comparative example 1B afterimmersion into acid solution.

FIG. 3 shows the release profiles of the capsules according to example 1and according to comparative example 1A.

FIG. 4 shows the release profiles of the capsules according to example 1and according to comparative example 1A (with a higher amount ofcoating).

FIG. 5 shows capsules according to example 2 and capsules according tocomparative example 2A after immersion into acid solution.

FIG. 6 shows capsules according to comparative example 2B afterimmersion into acid solution.

FIG. 7 shows capsules according to example 3 and capsules according tocomparative example 3A after immersion into acid solution.

FIG. 8 shows capsules according to comparative example 3B afterimmersion into acid solution.

FIG. 9 shows a dissolution profile of a capsule according to example 4.

FIG. 10 shows dissolution profiles of capsules according to example 5.

FIG. 11 shows dissolution profiles of capsules according to comparativeexample 5.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The capsule of the present invention in particular is for oraladministration, such as for oral administration of a pharmaceutical ornutritional ingredient.

The size of the capsule is not particularly limited and can be any usualsize, such as 000, 00, 0, 1, 2, 3, 4 or 5.

The capsule shell can be of any suitable material, such as gelatin,HPMC, pullulan or polyvinyl alcohol (PVA). HPMC and hard gelatincapsules are preferred. Hard gelatin capsules are particularlypreferred.

Capsules and in particular hard capsules are usually prepared by closinga capsule body with a cap. According to the invention, the gap betweenthe body and the cap of the capsule is sealed with a band. The band canbe of any usual material being compatible with the material of thecapsule shell. For example, the material of the band can be selectedfrom gelatin, hydroxypropylmethyl cellulose, polyvinyl alcohol,polyvinyl alcohol copolymer or a mixture of two or more of thesematerials. Preferably, the band seal is of the same material as thecapsule shell, such as a gelatin band, if hard-gelatin capsules areused. More preferably, the material of the band seal is gelatin orhydroxypropylmethyl cellulose.

The modified release coating of the capsule according to the inventionmay be a delayed release coating, such as an enteric coating, or acontrolled release coating. Combinations of these coatings are alsopossible.

The function of the coating is usually attained by a film forming agent,in particular a film forming polymer. Any usual film forming agent knownto the person skilled in the art for forming the desired coating may beused.

For an enteric coating the film forming agent usually comprises acompound which is insoluble in the gastrointestinal juice at a pH ofbelow 5 and which is soluble in the intestinal juice at a pH at or above5. Thus, this film forming agent dissolves in a pH dependent manner. Thefilm forming agent has a pH threshold which is the pH below which it isinsoluble and at or above which it is soluble. The pH of the surroundingmedium triggers the dissolution of the film forming agent. Thus, none(or essentially none) of the film forming agent dissolves below the pHthreshold. Once the pH of the surrounding medium reaches (or exceeds)the pH threshold, the film forming agent becomes soluble.

By “insoluble” it is understood that 1 g of the film forming agentrequires more than 10,000 ml of solvent (surrounding medium) to dissolveat a given pH. By “soluble”, it is understood that 1 g of the filmforming agent requires less than 10,000 ml, preferably less than 5,000ml, more preferably less than 1,000 ml, even more preferably less than100 ml or 10 ml of solvent to dissolve at a given pH. “Surroundingmedium” means the medium in the gastrointestinal tract, such as thegastric juice or intestinal juice. Alternatively, the surrounding mediummay be an in vitro equivalent of the medium in the gastrointestinaltract.

The normal pH of gastric juice is usually in the range of 1 to 3. Thefilm forming agent for intestinal, such as colon targeting should thusbe insoluble below pH 5 and should be soluble at or above pH 5. The filmforming agent therefore is usually insoluble in gastric juice. Suchmaterial may be referred to as an “enteric” material. The pH ofintestinal juice gradually increases to about 7 to 8 along the smallintestine. A film forming agent for intestinal targeting thereforebecomes soluble in the terminal ileum/colon and allows release of e.g.the active agent from the capsule. The film forming agent preferably hasa pH threshold of 6.5, more preferably of 7.

Examples of suitable film forming agents for intestinal targeting and inparticular for the preparation of the coating surrounding the capsuleare acrylate polymers, cellulose polymers and polyvinyl-based polymers,or other polymers. Examples of suitable cellulose polymers includecellulose acetate phthalate, cellulose acetate trimellitate, celluloseacetate succinate, hydroxypropylmethyl cellulose phthalate,hydroxypropylmethyl cellulose acetate succinate and carboxymethylethylcellulose acetate butyrate. Examples of suitable polyvinyl-basedpolymers include polyvinyl acetate phthalate.

In a preferred embodiment the material for intestinal targeting is aco-polymer of a (meth)acrylic acid and a (meth)acrylic acid C₁₋₄ alkylester, for instance, a co-polymer of methacrylic acid and methacrylicacid methyl ester. Suitable examples of such co-polymers are usuallyanionic. Furthermore, these co-polymers usually are not sustainedrelease polymethacrylates. The ratio of carboxylic acid groups tomethylester groups in these co-polymers determines the pH at which thecopolymer is soluble. The acid:ester ratio may be from about 2:1 toabout 1:3, e.g. about 1:1 or, about 1:2. The molecular weight of suchanionic co-polymers is usually from about 120,000 to 150,000, preferablyabout 135,000.

Known anionic poly(methacrylic acid/methyl methacrylate) co-polymersinclude Eudragit® L (pH threshold about 6.0), Eudragit® S (pH thresholdabout 7) and Eudragit® FS (pH threshold about 7). Eudragit® L 100-55which is a copolymer of methacrylic acid and ethylacetate and which hasa pH threshold of about 5.5 is also suitable. The Eudragit® copolymerscan be obtained from Evonik.

In addition or alternatively to the above described compounds having apH threshold the film forming agent for intestinal, such as colontargeting may comprise a compound which is susceptible to attack bycolonic bacteria, such as polysaccharides. Suitable polysaccharides arefor example starch, amylose, amylopectine, chitosan, chondroitinesulfate, cyclodextrine, dextrane, pullulan, carrageenan, scleroglucan,chitin, curdulan, pectin, guar gum, xanthan gum and levan.

Alternatively or additionally, the modified release coating can be acontrolled release coating. These coatings are able to provide releaseof the active substance after a predetermined time after administrationor a controlled release over time.

Galenical principles used to achieve the different release formstypically reduce the dissolution of the active ingredient; establishdiffusion barriers including osmotic systems and erosion systems. Withregards to functional coatings the focus is on establishment ofdiffusion barriers. Diffusion barriers can be established by membranescontrolling the diffusion being permeable or not; by using a controllingprinciple as pH or natural degradation during the GIT transit; by usinga controlled release matrix releasing an active ingredient contained inthe matrix controlled by diffusion; by using a membrane controlledosmotic effect, or by using a diffusion membrane eroding afterdegradation.

Suitable polymers for diffusion membranes that typically are gastricresistant are cellulose derivatives as cellulose acetate phthalate(CAP), Hydroxypropyl methylcellulose phthalate (HPMCP),polymethacrylates and polyvinylacetate phthalate.

In one embodiment of the present invention, the film forming agent doesnot comprise cellulose acetate. In another embodiment of the presentinvention, the film forming agent does not comprise cellulose acetatephthalate.

In one embodiment of the present invention, the film forming agent doesnot comprise hydroxypropylmethyl cellulose phthalate.

Suitable polymers for a controlled release matrix coating aredigestible, long chain (C8-050, especially C12-C40), substituted orunsubstituted hydrocarbons, such as fatty acids, fatty alcohols,glyceryl esters of fatty acids, mineral and vegetable oils and waxes,polyalkylene glycols, hydrophilic polymers, such as gums, celluloseethers, acrylic resins and protein derived materials, and in generalpolymers that are insoluble over the entire pH-range, and combinationsthereof.

Further suitable polymers are carboxy methylethylcellulose (CMEC) orethylcellulose which provide a release by diffusion but are not entirelygastric resistant. Further examples include polymethacrylate sustainedrelease polymers, such as Eudragit® RS, RL, NM and NE.

In one embodiment of the present invention, the film forming agent doesnot comprise ethylcellulose.

In one embodiment of the present invention, the film forming agent doesnot comprise Eudragit® RL PO. In another embodiment of the presentinvention, the film forming agent does not comprise Eudragit® FS, suchas Eudragit® FS30D.

Suitable polymers for an erosion system among others are cellulose etherderivatives and degradable natural polymers as polysaccharides.

With the materials mentioned above a person skilled in the art is ableto tailor the composition of the coatings in a way that the release ofthe active ingredient starts, or takes place, specifically at thetargeted site of the GIT. This can, among others, be achieved by themeans of introducing pores to make the membrane permeable, or morepermeable, by including pore formers and/or further excipients; byintroducing further excipients for erosion as e.g. using degradablenatural polymers as polysaccharides or synthetic polymers that dissolveat a certain pH.

Mixtures of two or more film forming agents may be used as appropriate.

Optionally, the modified release coating may additionally compriseconventional excipients, such as plasticizers for film formation (forexample triethylcitrate), anti-tacking agents (such as glycerylmonostearate or talc), colorants, pigments, solublilizers, dispersionagents and surfactants. For example such excipients may be included inamounts known to the skilled person of e.g. up to 30% by weight of thetotal weight of the coating.

A particular advantage of the present invention is that the amount offilm forming agent can be lower than usual. In fact, it was found that amodified release coating comprising a low amount of film forming agentbeing applied onto the capsule shell (with a band seal) with or withoutany precoat shows improved adhesion and can even impart improveddissolution properties to the capsule compared to a modified releasecoating comprising a higher amount of film forming agent. This does notonly save material and, thus, costs, but constitutes a surprisingbeneficial technical effect over prior art coated capsules. Thus, thefilm forming agent according to the invention can for example be presentin an amount of from about 1 mg to about 16 mg, preferably of from about2 mg to about 12 mg, more preferably of from about 2 mg to about 8 mg,such as from about 3.0 mg to ≦8.0 mg, more preferably of from >3.0 mg to≦8.0 mg, such as from about 3.1 mg to ≦8.0 mg, from about 3.2 mg to ≦8.0mg, from about 3.3 mg to ≦8.0 mg, from about 3.4 mg to ≦8.0 mg or fromabout 3.5 mg to ≦8.0 mg. In another embodiment, the amount of the filmforming agent is from about 2 mg to about 7 mg, more preferably offrom >2.0 mg to about 7.0 mg, such as from about 2.1 mg to about 7.0 mg,from about 2.2 mg to about 7.0 mg, from about 2.3 mg to about 7.0 mg,from about 2.4 mg to about 7.0 mg or from about 2.5 mg to about 7.0 mg,from about 3.0 mg to about 7.0 mg, from about 3.1 mg to about 7.0 mg,from about 3.2 mg to about 7.0 mg, from about 3.3 mg to about 7.0 mg,from about 3.4 mg to about 7.0 mg, from about 3.5 mg to about 7.0 mg.Even more preferred examples are of from about 2.0 mg to about 6.0 mg,from about 3.0 mg to about 6.0 mg and from about 3.5 mg to about 6.0 mgand most preferably from about 3 mg to about 5 mg, such as about 4 mg,each amount per cm² of the modified release coating.

In another embodiment of the present invention, the film forming agentaccording to the invention is not present in an amount of 3.0 mg per cm²of the modified release coating.

In one embodiment, the capsule according to the present invention isfilled with one or more pharmaceutically active ingredients. In apreferred embodiment, the one or more pharmaceutically activeingredients are selected from compounds used for the treatment ofinflammatory bowel disease, such as mesalazine, prednisone, methotrexateand antibiotics, such as metronidazole. Particularly preferred ismesalazine.

The capsule according to the invention may comprise one or moreadditional coatings, preferably above the modified release coating. Inthis context, “above” means that the additional coating may be coated onthe modified release coating. The additional coating may also be betweenthe capsule shell and the coating, although it is preferred that thereis no coating and in particular no precoat between the capsule shell andthe modified release coating. The additional coating may for example bepresent for increasing the stability of the capsule against humidity orfor increasing the visual appearance of the capsule.

Any of the above coatings including the modified release coating maycomprise one or more pharmaceutically active ingredients. Any coatingadditional to the modified release coating may consist of the one ormore pharmaceutically active ingredients.

In one embodiment, the one or more pharmaceutically active ingredientsin the above coatings have a combined effect together with thepharmaceutically active ingredient within the capsule.

In one embodiment, the capsule according to the present invention isfilled with one or more pharmaceutically active ingredients and theadditional coating above the modified release coating comprises orconsists of one or more pharmaceutically active ingredients. The one ormore pharmaceutically active ingredients within the capsule and withinthe additional coating can be the same or different. In a preferredembodiment the one or more pharmaceutically active ingredients withinthe capsule and within the coating are different.

In one embodiment, the capsule according to the present invention isfilled with one or more pharmaceutically active ingredients and themodified release coating comprises one or more pharmaceutically activeingredients. The one or more pharmaceutically active ingredients withinthe capsule and within the modified release coating can be the same ordifferent. In a preferred embodiment the one or more pharmaceuticallyactive ingredients within the capsule and within the modified releasecoating are different.

In one embodiment, the capsule according to the present invention isfilled with mesalazine (5-ASA) and the additional coating above themodified release coating comprises metronidazole, or an ester or saltthereof, in particular metronidazole benzoate.

In another embodiment, the capsule according to the present invention isfilled with mesalazine (5-ASA) and the coating comprises metronidazole,or an ester or salt thereof, in particular metronidazole benzoate.

In one embodiment, the capsule according to the present invention doesnot comprise an additional coating, in particular any additional coatingabove the modified release coating.

In another embodiment, the capsule according to the present inventiondoes not comprise an additional coating (in particular above themodified release coating) comprising carnuba wax or paraffin wax, inparticular waxes.

In a further embodiment, the capsule according to the present inventiondoes not comprise an coating, such as an additional coating, comprisingone or more pharmaceutically active ingredients.

The capsule according to the invention is filled with a non-liquid fill,such as a powder, granules, pellets or minitablets. Non-liquid fillsinclude semi-solids like waxy materials and materials being liquid whilefilling but becoming solid within the capsule. Non-liquid fills excludedispersions and solutions except these are contained for example withinpellets. The non-liquid fill may comprise a nutritional ingredientand/or an active pharmaceutical ingredient either alone or incombination with usual excipients.

In one embodiment, the capsule according to the present invention isfilled with a powder and the film forming agent according to theinvention is present in an amount of from >3.0 mg to ≦8.0 mg, such asfrom about 3.1 mg to ≦8.0 mg, from about 3.2 mg to ≦8.0 mg, from about3.3 mg to ≦8.0 mg, from about 3.4 mg to ≦8.0 mg or from about 3.5 mg to≦8.0 mg, and more preferably at about 4 mg, each amount per cm² of themodified release coating.

In another embodiment, the capsule according to the present invention isfilled with a powder and the film forming agent according to theinvention is present in an amount of from >2.0 mg to ≦8.0 mg, such asfrom about 2.1 mg to ≦8.0 mg, from about 2.2 mg to ≦8.0 mg, from about2.3 mg to ≦8.0 mg, from about 2.4 mg to ≦8.0 mg or from about 2.5 mg to≦8.0 mg, each amount per cm² of the modified release coating.

In yet a further embodiment, the capsule according to the presentinvention is filled with a powder or granules and the film forming agentis present in an amount of from >2.0 mg to about 7.0 mg, such as fromabout 2.1 mg to about 7.0 mg, from about 2.2 mg to about 7.0 mg, fromabout 2.3 mg to about 7.0 mg, from about 2.4 mg to about 7.0 mg, fromabout 2.5 g to about 7.0 mg, from about 3.0 mg to about 7.0 mg, fromabout 3.1 mg to about 7.0 mg, from about 3.2 mg to about 7.0 mg, fromabout 3.3 mg to about 7.0 mg, from about 3.4 mg to about 7.0 mg, or fromabout 3.5 mg to about 7.0 mg, such as from >2.0 mg to about 6.0 mg, fromabout 3.0 mg to about 6.0 mg and from 3.5 mg to about 6.0 mg, eachamount per cm² of the modified release coating.

In one embodiment, the capsule according to the present invention is notfilled with a powder.

In one embodiment, the capsule according to the present invention isfilled with pluralities of particles, such as pellets, minitablets,granules, etc.

In one embodiment, the capsule according to the present invention isfilled with an above described plurality of particles and the filmforming agent according to the invention is present in an amount offrom >3.0 mg to ≦8.0 mg, such as from about 3.1 mg to ≦8.0 mg, fromabout 3.2 mg to ≦8.0 mg, from about 3.3 mg to ≦8.0 mg, from about 3.4 mgto ≦8.0 mg or from about 3.5 mg to ≦8.0 mg, and more preferably at about4 mg, each amount per cm² of the modified release coating.

In another embodiment, the capsule according to the present invention isfilled with an above described plurality of particles and the filmforming agent according to the invention is present in an amount offrom >2.0 mg to ≦8.0 mg, such as from about 2.1 mg to ≦8.0 mg, fromabout 2.2 mg to ≦8.0 mg, from about 2.3 mg to ≦8.0 mg, from about 2.4 mgto ≦8.0 mg or from about 2.5 mg to ≦8.0 mg, each amount per cm² of themodified release coating.

In yet a further embodiment, the capsule according to the presentinvention is filled with an above described plurality of particles and afilm forming agent is present in an amount of from >2.0 mg to about 7.0mg, such as from about 2.1 mg to about 7.0 mg, from about 2.2 mg toabout 7.0 mg, from about 2.3 mg to about 7.0 mg, from about 2.4 mg toabout 7.0 mg, from about 2.5 g to about 7.0 mg, from about 3.0 mg toabout 7.0 mg, from about 3.1 mg to about 7.0 mg, from about 3.2 mg toabout 7.0 mg, from about 3.3 mg to about 7.0 mg, from about 3.4 mg toabout 7.0 mg, or from about 3.5 mg to about 7.0 mg, such as from >2.0 mgto about 6.0 mg, from about 3.0 mg to about 6.0 mg and from 3.5 mg toabout 6.0 mg, each amount per cm² of the modified release coating.

In one embodiment, the capsule according to the present invention is notfilled with an above described plurality of particles. In a preferredembodiment, the capsule according to the present invention is not filledwith minitablets or pellets.

The present invention further relates to a process to obtain the abovedescribed capsule comprising the steps of optionally filling the capsulebody with a non-liquid fill, closing the capsule with a cap, sealing thegap between body and cap with a band and applying a modified releasecoating onto the capsule shell.

Coating can be carried out by any usual method known to the personskilled in the art. For example, a film comprising the film formingagent and optional excipients can be applied as an organic solution, asan aqueous-organic coating emulsion, as an aqueous-organic coatingsolution, as an aqueous dispersion or as a neutralized aqueous solution.As organic liquids, alcohols and in particular ethanol may be used.

For example, the solution, emulsion or dispersion of the film formingagent and optionally excipients may be sprayed onto the capsule in anamount required for providing the desired amount of dry film formingagent per cm² of the final modified release coating.

The invention will now be further illustrated by the following exampleswhich are not intended to be construed as being limiting.

EXAMPLE 1

Size 1 hard gelatin capsules were filled with a model powder formulationcontaining methylene blue as marker. The capsules were closed and sealedwith a gelatin band. Without any precoat, the capsules were then coatedwith aqueous Eudragit L30D-55 in amounts of 4 mg/cm², 6 mg/cm², 10mg/cm² and 16 mg/cm², respectively, each relating to the dry amount offilm forming agent per cm² of the final coating.

COMPARATIVE EXAMPLE 1A

Capsules were manufactured in the same manner as in example 1 butwithout sealing the capsules with the gelatin band prior to the entericcoating.

COMPARATIVE EXAMPLE 1B

Capsules were manufactured in the same manner as in comparative example1A but with 3 mg/cm² HPMC precoat between the gelatin capsule shell andthe Eudragit L30D-55 enteric coating.

Evaluation of Capsules According to Example 1 and Comparative Examples1A and 1B

The acid resistance of the capsules obtained in example 1 andcomparative examples 1A and 1B was tested by immersing the capsules for120 minutes in 0.1 N HCl solution. After the capsules were recoveredfrom the solution, they were visually controlled. Due to the use ofmethylene blue as marker in the model powder formulation filled into thecapsules even small leakages could be easily observed.

The results of this test are shown in FIGS. 1 and 2. FIG. 1 shows thecapsules of example 1 being coated with 4 mg/cm² of the film formingagent after recovering from the acid solution. No deterioration of thecapsules or leakage was observed.

In contrast thereto, the capsules of comparative example 1A showedstrong deterioration and leakage (capsules turned blue) after immersionin the acid solution although they were coated with three-times theamount of enteric coating compared to example 1, namely 12 mg/cm² offilm forming agent. This comparative example demonstrates that sealingthe capsules with a band allows the use of much lower amounts of entericcoating material for obtaining capsules having even improved properties.

The capsules of comparative example 1B after immersion into the acidsolution are shown in FIG. 2. These capsules were prepared according tousual prior art methods using a HPMC precoat and being entericallycoated with 6 mg/cm² of the film forming agent. Despite the precoat thecapsules showed strong deterioration. Furthermore, the capsules turnedblue indicating that the marker substance leaked out of the capsules.Again, the banded capsules without any precoat according to theinvention (example 1) exhibit an improved acid resistance although theyare coated with a lower amount of enteric coating.

Furthermore, the release profiles of the capsules were measured using pH6.8 Hanks buffer. In vitro dissolution studies were performed on a USPtype II apparatus using a paddle speed of 50 rpm and a media temperatureof 37±0.5° C. Capsules were first tested in 900 ml 0.1 N HCl for 2 hoursfollowed by 8 or 10 hours in Hanks buffer (pH 6.8). The pH of the bufferwas stabilized at 6.8±0.05 by continuously sparging with 5% CO₂/95% O₂.Methylene blue absorbance measurements were taken at 5 minute intervals,with an absorbance wavelength of 663 nm. The composition per litre ofHanks buffer was 0.06 g of KH₂PO₄, 0.06 g Na₂HPO₄.2H₂O, 8.0 g NaCl, 0.4g KCl, 0.2 g MgSO₄.7H₂O, 0.139 g CaCl₂.2H₂O and 0.350 g NaHCO₃.

The release profiles of the capsules according to example 1 (bandedcapsules) and of the capsules of comparative example 1A (non-bandedcapsules) are shown in FIG. 3. Both capsules were coated with 4 mg/cm²of the film forming agent. As expected from the above acid resistancetest, release of the model active pharmaceutical ingredient (API) fromthe non-banded capsules according to comparative example 1A startedalready under the simulated stomach conditions in the 0.1 N HClsolution. Furthermore, the non-banded capsules did not release all ofthe API even after prolonged time in Hanks buffer. In contrast thereto,the capsules according to the invention (banded; example 1) did notrelease any of the API under the simulated stomach conditions butreleased their complete API content after a lag time of about 20 minutesin the bicarbonate buffer.

FIG. 4 shows a comparison of the release profiles of banded capsulesaccording to example 1 coated with 4 mg/cm² of the film forming agentand non-banded capsules according to example 1A being coated with asmuch as 16 mg/cm² of the film forming agent. While the significantincrease in the amount of enteric coating suppressed the prematurerelease of the API under simulated stomach conditions, the API wasreleased at a later lag time, which could results in a too late releasein vivo leading to lower oral bioavailability of drugs preferablyabsorbed in the proximal small intestine. Only up to about 60% of APIwas released even after prolonged time in the bicarbonate buffersolution.

EXAMPLE 2

Capsules were prepared in the same manner as in example 1 but usingorganic Eudragit L100-55 for preparing the enteric coating.

COMPARATIVE EXAMPLE 2A

Capsules were prepared in the same manner as in example 2 but withoutsealing the capsules with the gelatin band prior to the enteric coating.

COMPARATIVE EXAMPLE 2B

Capsules were prepared in the same manner as in comparative example 2Abut using a precoat of 3 mg/cm² of HPMC prior to the enteric coating.

Evaluation of Capsules According to Example 2 and Comparative Examples2A and 2B

The acid resistance of the capsules obtained in example 2 andcomparative examples 2A and 2B were tested as described above withrespect to the capsules of example 1 and comparative examples 1A and 1B.The results are shown in FIGS. 5 and 6 for the capsules obtained inexample 2 being coated with 4 mg/cm² of the film forming agent (FIG. 5),the capsules obtained in comparative example 2A being coated with 16mg/cm² of the film forming agent (FIG. 5) and the capsules obtained incomparative example 2B being coated with a precoat and with 4 mg/cm² ofthe film forming agent (FIG. 6).

As can be seen, the capsules according to the invention (example 2)exhibited no deterioration or leakage while the capsules being coatedwith even four times the amount of enteric coating obtained incomparative example 2A and the capsules being coated with the sameamount of enteric coating as the capsules of example 2 but additionallycomprising a precoat obtained in comparative example 2B exhibited strongdeterioration and leakage.

EXAMPLE 3

Size 1 hard HPMC capsules were filled with a model powder formulationcontaining methylene blue as marker. The capsules were closed and sealedwith a HPMC band. Without any precoat, the capsules were then coatedwith an amount of 4 mg/cm² aqueous Eudragit L30D-55, relating to the dryamount of film forming agent per cm² of the final coating.

COMPARATIVE EXAMPLE 3A

Capsules were manufactured in the same manner as in example 3 butwithout sealing the capsules with the HPMC band prior to the entericcoating.

COMPARATIVE EXAMPLE 3B

Capsules were manufactured in the same manner as in comparative example3A but with 3 mg/cm² HPMC precoat between the HPMC capsule shell and theEudragit L30D-55 enteric coating.

EXAMPLE 4

Size 1 hard gelatin capsules were filled with 314 mg of mesalazine(5-ASA). The capsules were closed and sealed with a gelatin band.Without any precoat, the capsules were then coated with aqueous EudragitL30D-55 in an amount of 4 mg/cm² relating to the dry amount of filmforming agent per cm² of the final coating. Then the capsules werecoated with an additional coating comprising 60 mg of metronidazolebenzoate.

The release profiles of the capsules were measured using pH 6.8 Hanksbuffer. In vitro dissolution studies were performed on a USP type IIapparatus using a paddle speed of 50 rpm and a media temperature of37±0.5° C. Capsules were first tested in 900 ml 0.1 N HCl for 2 hoursfollowed by 8 or 10 hours in Hanks buffer (pH 6.8). The pH of the bufferwas stabilized at 6.8±0.05 by continuously sparging with 5% CO₂/95% O₂.Metronidazole benzoate and mesalazine measurements were taken at 5minute intervals. The composition per litre of Hanks buffer was 0.06 gof KH₂PO₄, 0.06 g Na₂HPO₄.2H₂O, 8.0 g NaCl, 0.4 g KCl, 0.2 g MgSO₄.7H₂O,0.139 g CaCl₂.2H₂O and 0.350 g NaHCO₃. The results are shown in FIG. 9.

EXAMPLE 5

Size 1 hard gelatin capsules were filled with 312 mg of mesalazine(5-ASA). The capsules were closed and sealed with a gelatin band.Without any precoat, the capsules were then coated with a coatingcomprising metronidazole benzoate in Eudragit® RS in amounts of 20 mg (4mg/cm² Eudragit® RS) and 60 mg (12 mg/cm² Eudragit® RS), respectively.

COMPARATIVE EXAMPLE 5

Capsules were manufactured in the same manner as in example 5 butwithout sealing the capsules with the gelatin band prior to the coating.

Evaluation of Capsules According to Example 5 and Comparative Example 5

The release profiles of the capsules were measured using pH 6.8Phosphate buffer. In vitro dissolution studies were performed on a USPtype II apparatus using a paddle speed of 50 rpm and a media temperatureof 37±0.5° C. Capsules were first tested in 900 ml 0.1 N HCl for 2 hoursfollowed by 8 or 10 hours in Phosphate buffer (pH 6.8). Metronidazolebenzoate and mesalazine measurements were taken at 5 minute intervals.

The release profiles of the capsules according to example 5 (bandedcapsules) and of the capsules of comparative example 5 (non-bandedcapsules) are shown in FIGS. 10 and 11. Both capsules were coated with 4mg/cm² and 12 mg/cm² of the film forming agent, respectively.

The capsules according to the invention (example 5) did not releasesignificant amounts of both, metronidazole benzoate and mesalazine underthe simulated conditions of the intestine during a period of up to 450minutes, irrespective of whether the capsules were coated with 4 mg/cm²or 12 mg/cm² of the film forming agent (FIG. 10). In contrast thereto,the non-banded capsules (comparative example 5) did release mesalazinebenzoate under the simulated conditions of the intestine starting from160 minutes (4 mg/cm²) or 210 minutes (12 mg/cm²), respectively.Metronidazole benzoate was not released under the above conditions (FIG.11).

1. A capsule comprising a body, a cap and a gap therebetween, saidcapsule further containing a non-liquid fill and comprising a modifiedrelease coating, characterized in that the capsule is band sealed belowthe modified release coating.
 2. The capsule according to claim 1,wherein said capsule shell is selected from the group consisting of agelatin shell, hydroxypropylmethyl cellulose shell, a pullulan shell anda PVA-based shell.
 3. The capsule according to claim 1, wherein the bandseal is a gelatin or HPMC band sealing the gap between said body and capof the capsule.
 4. The capsule according to claim 1, wherein themodified release coating is selected from the group consisting of adelayed release coating, a controlled release coating, and combinationsthereof.
 5. The capsule according to claim 4, wherein said modifiedrelease coating is an enteric coating and said film forming agent isselected from the group consisting of acrylate polymers, cellulosepolymers, polyvinyl-based polymers and mixtures thereof.
 6. The capsuleaccording to claim 5, wherein said film forming agent is selected fromthe group consisting of co-polymers of (meth)acrylic acid and a(meth)acrylic acid C₁₋₄ alkyl ester, cellulose acetate phthalate,cellulose acetate trimellitate, cellulose acetate succinate,hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl celluloseacetate succinate, carboxymethylethyl cellulose acetate butyrate,polyvinyl acetate phthalate, and mixtures thereof.
 7. The capsuleaccording to claim 6, wherein said film forming agent is selected fromthe group consisting of Eudragit L, Eudragit S and Eudragit FS.
 8. Thecapsule according to claim 1, wherein the modified release coatingcomprises a film forming agent which is present in an amount rangingfrom about 1 mg to about 16 mg per cm² of the modified release coating.9. The capsule according to claim 1, wherein the modified releasecoating additionally comprises at least one excipient selected from thegroup consisting of plasticizers, anti-tacking agents, colourants,pigments, solubilizers, dispersion agents and surfactants.
 10. Thecapsule according to claim 1, further comprising one or more additionalcoatings.
 11. The capsule according to claim 1, wherein the capsule doesnot comprise any precoat between the capsule shell and the modifiedrelease coating.
 12. The capsule according to claim 1, wherein thecapsule contains a filling selected from the group consisting of powder,granules, pellets, minitablets, and combinations thereof.
 13. Thecapsule according to claim 1, wherein the non-liquid fill comprises anutritional ingredient, an active pharmaceutical ingredient, or acombination thereof.
 14. A process for manufacturing a capsule accordingto any claim 1, wherein said process comprises the steps of (i) fillinga capsule body with a non-liquid fill, (ii) closing the capsule with acap, (iii) sealing the gap between body and cap with a band and (iv)applying a modified release coating onto the capsule shell.
 15. Theprocess according to claim 14, wherein the modified release coating isapplied onto the capsule shell in the form of an aqueous or anon-aqueous liquid composition that includes a film forming agent. 16.The capsule according to claim 1, wherein the modified release coatingcomprises a film forming agent which is present in an amount of fromabout 2 mg to about 12 mg per cm² of the modified release coating.